Perioperative GLP‐1 Receptor Agonist Use and 30‐Day Outcomes After Breast Cancer Surgery: A Retrospective Cohort Study
World Journal of Surgery · 2026
DOI: 10.1002/wjs.70487 ↗At a glance
Kohortenstudie in World Journal of Surgery, 2026. Written by Nuha Alsaleh and 4 co-authors. Institution: Department of Surgery, College of Medicine, King Saud University, Riyadh, Saudi Arabia. Major MEDLINE topics: Breast Neoplasms, Glucagon-Like Peptide-1 Receptor Agonists, Postoperative Complications, Hypoglycemic Agents. Cited 1 times so far (Crossref); 20 references. The full text is freely available in PubMed Central.
Abstract (original language)
Background
Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) are increasingly prescribed for diabetes and obesity, but their perioperative safety in breast cancer surgery remains uncertain. This study evaluated the association between perioperative GLP‐1 RA use and 30‐day postoperative outcomes after breast cancer surgery. Materials and Methods This retrospective cohort study included adults undergoing breast cancer surgery at a tertiary center (January 2024–August 2025). Exposure was active GLP‐1 RA use within 30 days preoperatively, verified via pharmacy records. The primary outcome was a composite 30‐day surgical morbidity endpoint (surgical site infection [SSI], flap necrosis ≥ grade II, seroma requiring aspiration, or implant/expander loss). Secondary outcomes included venous thromboembolism (VTE), readmission, reoperation, and length of stay. Multivariable regression and inverse probability of treatment weighting (IPTW) addressed confounding.
Results
The analytic cohort comprised 750 patients (209 exposed, 541 unexposed; median age 51 years). Exposed patients had higher body mass index and diabetes prevalence. After adjustment, GLP‐1 RA exposure was not associated with SSI (adjusted odds ratio [AOR] 1.28, 95% CI 0.81–2.03), seroma (AOR 1.22, 95% CI 0.83–1.79), or flap necrosis ≥ grade II (AOR 1.41, 95% CI 0.83–2.40). No secondary outcome showed independent association with exposure. Prolonged length of stay (≥ 3 days) occurred in 26.8% of patients overall and was attributable primarily to drain management requirements, extent of surgery, and metabolic comorbidity rather than GLP‐1 RA exposure.
Conclusion
Perioperative GLP‐1 RA use was not independently associated with increased short‐term complications after breast cancer surgery. Multicenter studies are needed to confirm safety across settings.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Surgery, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
- Faculty of Medicine, Ain Shams University, Cairo, Egypt.
- King Saud University Medical City, King Khalid University Hospital, Riyadh, Saudi Arabia.
- Oncology Center, King Saud University Medical City, King Saud University, Riyadh, Saudi Arabia.
ORCID profiles: Nuha Alsaleh, Noha A Seif-Eldein, Ahmed M El Malky, Hashem Al Hashem
Cite
APA
Alsaleh, N., Seif-Eldein, N. A., El Malky, A. M., Al Hashem, H., & Idriss, H. (2026). Perioperative GLP‐1 Receptor Agonist Use and 30‐Day Outcomes After Breast Cancer Surgery: A Retrospective Cohort Study. World Journal of Surgery. https://doi.org/10.1002/wjs.70487
Vancouver
Alsaleh N, Seif-Eldein NA, El Malky AM, Al Hashem H, Idriss H. Perioperative GLP‐1 Receptor Agonist Use and 30‐Day Outcomes After Breast Cancer Surgery: A Retrospective Cohort Study. World Journal of Surgery. 2026. doi:10.1002/wjs.70487
BibTeX
@article{Alsaleh2026,
author = {Alsaleh, Nuha and Seif-Eldein, Noha A and El Malky, Ahmed M and Al Hashem, Hashem and Idriss, Hend},
title = {Perioperative GLP‐1 Receptor Agonist Use and 30‐Day Outcomes After Breast Cancer Surgery: A Retrospective Cohort Study},
journal = {World Journal of Surgery},
year = {2026},
doi = {10.1002/wjs.70487}
}
EUVIMED